(-)-Huperzine A
Based on 6 publication(s) in Google Scholar
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 102518-79-6
- Formula: C15H18N2O
- Molecular Weight:242.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (-)-Huperzine A
More- Cell Metab. 2022 Mar 1;34(3):424-440.e7. [Abstract]
- Eur J Pharmacol. 2024 Nov 15:983:177004. [Abstract]
- ACS Omega. 2025 Aug 21;10(34):39192-39202. [Abstract]
- J Pharm Biomed Anal. 2025 Apr 15:256:116669. [Abstract]
- bioRxiv. 2024 Apr 3:2023.06.02.542933. [Abstract]
- Aging (Albany NY). 2022 Oct 12;14(19):8077-8094. [Abstract]
All iGluR Isoforms
More
Biological Activity
|
AChE |
NMDA Receptor |
(-)-Huperzine A (1 μM; 2 hours) attenuates Aβ23-35 (20 μM)-induced neuronal injury[2].
(-)-Huperzine A (100 μM) reversibly inhibits the NMDA-induced current (IC50=126 μM) in whole-cell voltage-clamp recording in CA1 pyramidal neurons acutely dissociated from rat hippocampus[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (220-280 g)[5]
-
Dosage:0.1 mg/kg, 0.2 mg/kg
-
Administration:Intraperitoneal injection, daily, for 12 days
-
Result:Partly reversed the down-regulation of anti-apoptotic Bcl-2 and the up-regulation of pro-apoptotic Bax and P53 proteins and reduced the apoptosis that normally followed b-amyloid injection; alleviated the cognitive dysfunction induced by b-amyloid protein-(1-40).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 102518-79-6
-
Appearance Solid
-
Molecular Weight 242.32
-
Formula C15H18N2O
-
Color White to off-white
-
SMILES
O=C1NC2=C([C@@](/C3=C\C)(N)CC(C)=C[C@@]3([H])C2)C=C1
-
Synonyms
Huperzine A
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]2022 Mar 1;34(3):424-440.e7. PMID: 35150639 -
Eur J Pharmacol
Huperzine A protected against ferroptosis via activating PI3K/Akt signaling in lipopolysaccharide induced acute lung injury. [Abstract]2024 Nov 15:983:177004. PMID: 39278310 -
ACS Omega
2025 Aug 21;10(34):39192-39202. PMID: 40918390 -
J Pharm Biomed Anal
Cellulose filter paper immobilized acetylcholinesterase for rapid screening of enzyme inhibitors in Phyllanthus emblica L. [Abstract]2025 Apr 15:256:116669. PMID: 39818021 -
bioRxiv
An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]2024 Apr 3:2023.06.02.542933. PMID: 37333363 -
Aging (Albany NY)
Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets. [Abstract]2022 Oct 12;14(19):8077-8094. PMID: 36227154
Solvent & Solubility
DMSO : 50 mg/mL (206.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (20.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (20.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (423 KB)
- English - EN (423 KB)
- Français - FR (423 KB)
- Deutsch - DE (423 KB)
- Norwegian - NO (423 KB)
- Español - ES (423 KB)
- Swedish - SV (423 KB)
- Italian - IT (423 KB)
- Korean - KR (423 KB)
- Portuguese - PT (423 KB)
-
Handling Instructions (2659 KB)
References
[1]. MA Xiao-Chao, XIN Jian, WANG Hai-Xue, et al. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol ogica Sinica, 2003, 24(3):247-250. [Content Brief]
[2]. Rui Wang, et al. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 Jan;27(1):1-26. [Content Brief]
[3]. J M Zhang, et al. Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.Neuroscience. 2001;105(3):663-9 [Content Brief]
[4]. Maung Kyaw Moe Tun, et al. The pharmacology and therapeutic potential of (−)-huperzine A. J Exp Pharmacol. 2012; 4: 113–123. [Content Brief]
[5]. R Wang, et al. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol. 2001 Jun 15;421(3):149-56. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1268 mL | 20.6339 mL | 41.2677 mL | 103.1694 mL |
| 5 mM | 0.8254 mL | 4.1268 mL | 8.2535 mL | 20.6339 mL | |
| 10 mM | 0.4127 mL | 2.0634 mL | 4.1268 mL | 10.3169 mL | |
| 15 mM | 0.2751 mL | 1.3756 mL | 2.7512 mL | 6.8780 mL | |
| 20 mM | 0.2063 mL | 1.0317 mL | 2.0634 mL | 5.1585 mL | |
| 25 mM | 0.1651 mL | 0.8254 mL | 1.6507 mL | 4.1268 mL | |
| 30 mM | 0.1376 mL | 0.6878 mL | 1.3756 mL | 3.4390 mL | |
| 40 mM | 0.1032 mL | 0.5158 mL | 1.0317 mL | 2.5792 mL | |
| 50 mM | 0.0825 mL | 0.4127 mL | 0.8254 mL | 2.0634 mL | |
| 60 mM | 0.0688 mL | 0.3439 mL | 0.6878 mL | 1.7195 mL | |
| 80 mM | 0.0516 mL | 0.2579 mL | 0.5158 mL | 1.2896 mL | |
| 100 mM | 0.0413 mL | 0.2063 mL | 0.4127 mL | 1.0317 mL |
(-)-Huperzine A Related Classifications
HY-17387 Related Classifications
Powered by Bioz